In this review, an expert panel discusses possible factors inhibiting the ongoing acceptance of anti-TNF-α biosimilars, as well as possible strategies to support their more consistent use to accelerate earlier access to anti-TNF-α agents for management of IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.